- Home
- PBYI vs SSSS Comparison
PBYI vs SSSS Comparison
Compare PBYI & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- SSSS
- Stock Information
- Founded
- PBYI 2010
- SSSS 2010
- Country
- PBYI United States
- SSSS United States
- Employees
- PBYI N/A
- SSSS N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- PBYI Health Care
- SSSS Finance
- Exchange
- PBYI Nasdaq
- SSSS Nasdaq
- Market Cap
- PBYI 171.7M
- SSSS 138.2M
- IPO Year
- PBYI N/A
- SSSS N/A
- Fundamental
- Price
- PBYI $4.64
- SSSS $9.10
- Analyst Decision
- PBYI Strong Buy
- SSSS Strong Buy
- Analyst Count
- PBYI 1
- SSSS 4
- Target Price
- PBYI $7.00
- SSSS $9.50
- AVG Volume (30 Days)
- PBYI 648.1K
- SSSS 263.3K
- Earning Date
- PBYI 11-06-2025
- SSSS 11-06-2025
- Dividend Yield
- PBYI N/A
- SSSS 10.96%
- EPS Growth
- PBYI 434.29
- SSSS N/A
- EPS
- PBYI 0.97
- SSSS 2.22
- Revenue
- PBYI $238,062,000.00
- SSSS $2,784,381.00
- Revenue This Year
- PBYI N/A
- SSSS $6.95
- Revenue Next Year
- PBYI N/A
- SSSS N/A
- P/E Ratio
- PBYI $4.76
- SSSS $4.11
- Revenue Growth
- PBYI 8.63
- SSSS N/A
- 52 Week Low
- PBYI $2.32
- SSSS $3.77
- 52 Week High
- PBYI $6.07
- SSSS $9.50
- Technical
- Relative Strength Index (RSI)
- PBYI 49.99
- SSSS 64.23
- Support Level
- PBYI $4.49
- SSSS $8.63
- Resistance Level
- PBYI $5.22
- SSSS $8.75
- Average True Range (ATR)
- PBYI 0.26
- SSSS 0.17
- MACD
- PBYI -0.12
- SSSS 0.03
- Stochastic Oscillator
- PBYI 22.33
- SSSS 55.56
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.